We provide trade advice to complement the prevailing
expert consensus on Enzo Biochem. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Enzo Biochem income statement, its balance sheet, and the statement of cash flows. Potential Enzo Biochem investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Enzo Biochem investors may use each financial statement separately, they are all related. The changes in Enzo Biochem's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enzo Biochem's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Enzo Biochem
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Enzo Biochem performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Enzo Biochem shares is the value that is considered the true value of the share. If
the intrinsic value of Enzo is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Enzo Biochem. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring Enzo Biochem on a daily basis if you are holding a position in it. Enzo Biochem is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Enzo Biochem stock to be traded above the $1 level to remain listed. If Enzo Biochem stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How effective is Enzo Biochem in utilizing its assets?
Enzo Biochem reports assets on its Balance Sheet. It represents the amount of Enzo resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Enzo Biochem aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Health Care Providers & Services space. To get a better handle on how balance sheet or income statements item affect Enzo volatility, please check the breakdown of all its
fundamentals.
Are Enzo Biochem Earnings Expected to grow?
The
future earnings power of Enzo Biochem involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Enzo Biochem factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Enzo Biochem
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Enzo
expected earnings.
Enzo Biochem Gross Profit
Enzo Biochem Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Enzo Biochem previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Enzo Biochem Gross Profit growth over the last 10 years. Please check Enzo Biochem's
gross profit and other
fundamental indicators for more details.
Breaking it down a bit more
Institutional investors typically avoid acquiring a high percentage of Enzo Biochem stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Enzo Biochem is distributed among investors.
Ownership Allocation
Enzo Biochem holds a total of fourty-seven million nine hundred thousand
outstanding shares. Over half of Enzo Biochem outstanding shares are owned by
other corporate entities. These other corporate entities are typically referred to corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these
institutions are subject to different rules and regulation than regular investors in Enzo Biochem. Please watch out for any change in the
institutional holdings of Enzo Biochem as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
| Retail Investors30.64% | Insiders7.17% | Institutions62.19% |
| Retail Investors | 30.64 |
| Insiders | 7.17 |
| Institutions | 62.19 |
| 2018 | 2019 | 2020 | 2021 (projected) |
Revenues USD | 81.17 M | 76.02 M | 68.42 M | 76.41 M | Revenues | 81.17 M | 76.02 M | 68.42 M | 76.41 M |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enzo Biochem has an asset utilization ratio of 75.54 percent. This suggests that the company is making $0.76 for each dollar of assets. An increasing asset utilization means that Enzo Biochem is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets77.6 M | Assets Non Current33.9 M | |
| Current Assets | 77.58 Million | 65.29 |
| Assets Non Current | 33.85 Million | 28.49 |
| Goodwill | 7.38 Million | 6.21 |
Our take on Enzo Biochem small slide
Enzo Biochem current potential upside rises over 5.81. Enzo Biochem shows above-average downside volatility for the selected time horizon. We advise investors to inspect Enzo Biochem further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Enzo Biochem future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Enzo Biochem
While other entities in the diagnostics & research industry are either recovering or due for a correction, Enzo Biochem may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 15th of March 2021, our analysis shows that Enzo Biochem follows the market closely. The company is
undervalued and projects
quite high probability of distress for the next 2 years. Our primary 30 days buy vs. sell advice on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Enzo Biochem. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com